Insulin Glargine (rDNA origin) Injection

June 2020
AHFS Consumer Medication Information;Jun2020, p1
Insulin glargine is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood) who need insulin to control their diabetes. In patients with type 1 diabetes, insulin glargine must be used with another type of insulin (a short-acting insulin). In patients with type 2 diabetes, insulin glargine also may be used with another type of insulin or with oral medication(s) for diabetes. Insulin glargine is a long-acting, man-made version of human insulin. Insulin glargine works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar.


Related Articles

  • Insulin aspart in patients with gestational diabetes mellitus and pregestational diabetes mellitus. Deepaklal, M. C.; Joseph, Kurian; Rekha, Kurian; Nandita, Thakkar // Indian Journal of Endocrinology & Metabolism;Sep/Oct2015, Vol. 19 Issue 5, p658 

    Aims: This study was undertaken to assess the effectiveness and safety of insulin aspart in patients with gestational and pregestational diabetes. Settings and Design: An open-label, prospective, nonrandomized, comparative, and observational study conducted at single center in India. Subjects...

  • BACK ON TRACK. HOPE, TONI GERBER // Better Homes & Gardens;Nov2015, Vol. 93 Issue 11, p163 

    The article focuses on the threat of diabetes and offers suggestions for reducing diabetes, which includes focusing of blood sugar levels and weight loss.

  • Troglitazone for insulin-resistant diabetes.  // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1985 

    Presents information about the approval of the Food and Drug Administration on troglitazone (Rezulin) as the first anti-diabetes drug that targets the underlying cause of type II diabetes mellitus. Required dosage of troglitazone for patients receiving insulin injection; Most common adverse...

  • Injectable leptin appears to be safe and effective for weight loss.  // Modern Medicine;Aug98, Vol. 66 Issue 8, p52 

    Presents an abstract of a study on the effectiveness of injectable hormone leptin on blood glucose levels, presented by Andrew Greenberg and Robert Consodine at the American Diabetes Association's 58th scientific sessions.

  • Amelioration of insulin resistance by Rk1 + Rg5 complex under endoplasmic reticulum stress conditions. Shree Priya Ponnuraj; Fayeza Siraj; Sera Kang; Hae Yong Noh; Jin-Woo Min; Yeon-Ju Kim; Deok-Chun Yang // Pharmacognosy Research;Oct-Dec2014, Vol. 6 Issue 4, p292 

    Background: Diabetes mellitus is a metabolic syndrome exaggerated by stress conditions. Endoplasmic reticulum stress (ERS) impairs the insulin signaling pathway making the diabetic conditions worsen. Pharmacological agents are supplied externally to overcome this malfunction. Ginsenosides from...

  • Effects of insulin resistance on myometrial growth. Zhi-Min Hou; Qian Sun; Yan-Zhi Liu; Tie-Fu Chen; Na Tang // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 1, p1552 

    To observe the effects of insulin resistance on gonadal steroid hormone stimulation and the myometrial growth of female rats in order to elucidate the relationship between insulin resistance and the development of uterine leiomyomas. We divided 180 nonpregnant female Wistar rats into three...

  • Improved Postprandial Glycemic Control With Insulin Aspart. Lindholm, Anders; McEwen, John; Riis, Anders P. // Diabetes Care;May99, Vol. 22 Issue 5, p801 

    Presents information on a study which compared the postprandial serum glucose control after administration of insulin aspart, a rapid-acting insulin analog, with that of unmodified human insulin in patients with type one diabetes. Research design and methods; Results; Conclusions.

  • Insulin-Like Growth Factors and Metabolic Syndrome in Obese Children. Inzaghi, Elena; BaldiniĀ Ferroli, Barbara; Fintini, Danilo; Grossi, Armando; Nobili, Valerio; Cianfarani, Stefano // Hormone Research in Paediatrics;Jul2017, Vol. 87 Issue 6, p400 

    Background/Aims: Insulin-like growth factor (IGF)-I is related to cardiometabolic risk in adults, whereas the metabolic role of IGF-II is unclear. The aim of this study was to assess IGFs in obese children and correlate them with metabolic syndrome (MetS) components. Methods: This is a...

  • Insulin degludec in Phase 3 trials.  // Clinical Cardiology Alert;May2011 Pharmacology, p2 

    The article reports that insulin degludec, an ultralong-acting insulin, is currently undergoing Phase 3 trials, and discusses a study which concluded that insulin degludec provides glycemic control without adverse events (AEs) and may reduce dosing frequency.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics